Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT C KWUN

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1457338162
CMS profile
461770
Location
SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$28,766.05

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT C KWUN

NPI 1457338162 · CMS profile ID 461770

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457338162?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT C KWUN, NPI 1457338162, CMS profile ID 461770. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457338162?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROBERT C KWUN, NPI 1457338162, CMS profile ID 461770. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457338162?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROBERT C KWUN, NPI 1457338162, CMS profile ID 461770, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1457338162?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $28,766.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $9.3801/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114094329 CMS
Regeneron Healthcare Solutions, Inc. $49.6301/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114094331 CMS
Regeneron Healthcare Solutions, Inc. $58.9501/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114094333 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $123,046.99 140
PY2020 $38,998.46 37
PY2021 $19,319.64 36
PY2022 $22,194.20 37
PY2023 $85,949.73 87
PY2024 $28,766.05 53
PY2025 $16,123.49 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $446,282.55 285
PY2024 Principal investigator $99,662.62 16
PY2023 Principal investigator $145,358.30 30
PY2022 Principal investigator $216,804.10 24
PY2021 Principal investigator $327,709.20 19
PY2020 Principal investigator $244,235.00 8
PY2019 Principal investigator $160,154.90 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

285 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $44,391.00 12/22/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220814003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.05 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $742.50 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $310.40 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279556
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $310.50 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.05 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.35 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279622
Principal investigator 1 Boehringer Ingelheim International GmbH $89.10 12/10/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636073
Principal investigator 1 Boehringer Ingelheim International GmbH $20.47 12/10/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636075
Principal investigator 1 Boehringer Ingelheim International GmbH $185.03 12/10/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636077
Principal investigator 1 Boehringer Ingelheim International GmbH $185.03 12/10/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636079
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 12/08/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636071
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 12/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 12/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267101
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636037
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636041
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636047
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636053
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636055
Principal investigator 1 Boehringer Ingelheim International GmbH $315.20 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636057
Principal investigator 1 Boehringer Ingelheim International GmbH $337.50 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636061
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636063
Principal investigator 1 Boehringer Ingelheim International GmbH $71.55 11/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636065
Principal investigator 1 Boehringer Ingelheim International GmbH $3,767.85 11/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636051
Principal investigator 1 Boehringer Ingelheim International GmbH $1,241.90 11/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636031
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 11/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636035
Principal investigator 1 ABBVIE INC. $64.80 11/19/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202524692
Principal investigator 1 Boehringer Ingelheim International GmbH $38.00 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635893
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635895
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635897
Principal investigator 1 Boehringer Ingelheim International GmbH $111.36 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635899
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636039
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636043
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636045
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636049
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/19/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/19/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,947.60 11/19/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/19/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/19/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/14/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/14/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/14/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,638.60 11/14/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $386.82 11/13/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260585
Principal investigator 1 Boehringer Ingelheim International GmbH $4,334.85 11/12/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 11/12/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184259619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/12/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184259621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 11/12/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184259623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/12/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184259625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/12/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184259627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/12/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184259629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 11/12/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184259631
Principal investigator 1 Boehringer Ingelheim International GmbH $6,532.65 11/05/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636067
Principal investigator 1 ABBVIE INC. $2,783.57 11/03/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202520045
Principal investigator 1 Astellas Pharma Global Development $1,850.00 11/03/2025 Non-covered Recipient Entity
Retina Associates of Utah P.C.
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185496
Principal investigator 1 Astellas Pharma Global Development $1,850.00 11/03/2025 Non-covered Recipient Entity
Retina Associates of Utah P.C.
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185500
Principal investigator 1 Boehringer Ingelheim International GmbH $1,831.95 11/03/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636033
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635889
Principal investigator 1 Boehringer Ingelheim International GmbH $5,312.25 10/29/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635985
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 10/29/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636025
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 10/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636081
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 10/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636083
Principal investigator 1 Boehringer Ingelheim International GmbH $215.76 10/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636085
Principal investigator 1 Boehringer Ingelheim International GmbH $4,334.85 10/22/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636029
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635975
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635977
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635979
Principal investigator 1 Boehringer Ingelheim International GmbH $166.04 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635981
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635983
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635987
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635991
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635993
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635995
Principal investigator 1 Boehringer Ingelheim International GmbH $94.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635997
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635999
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636001
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636003
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636005
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636009
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636011
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636013
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636015
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636017
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636021
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636023
Principal investigator 1 Boehringer Ingelheim International GmbH $89.10 10/16/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636027
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,378.00 10/13/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813999
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $57,931.00 10/10/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813997
Principal investigator 1 Boehringer Ingelheim International GmbH $3,767.85 10/09/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635989
Principal investigator 1 Boehringer Ingelheim International GmbH $1,831.95 10/09/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636007
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 10/03/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220636019
Principal investigator 1 Janssen Research & Development, LLC $8,083.00 10/03/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1175425034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 10/03/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245893
Principal investigator 1 Astellas Pharma Global Development $1,850.00 10/02/2025 Non-covered Recipient Entity
Retina Associates of Utah P.C.
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185494
Principal investigator 1 Astellas Pharma Global Development $1,100.00 10/02/2025 Non-covered Recipient Entity
Retina Associates of Utah P.C.
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185498
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635887
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,072.00 10/01/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220814001
Principal investigator 1 Genentech, Inc. $9,787.00 09/26/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211645808
Principal investigator 1 Genentech, Inc. $269.00 09/26/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211645823
Principal investigator 1 Genentech, Inc. $1,680.00 09/26/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211645843
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 09/24/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635877
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 09/24/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635879
Principal investigator 1 Boehringer Ingelheim International GmbH $83.52 09/24/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635881
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 09/24/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635883
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 09/24/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635885
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 09/15/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635971
Principal investigator 1 Boehringer Ingelheim International GmbH $4,476.60 09/15/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635973
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,819.00 09/11/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813985
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,074.00 09/11/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813987
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,278.00 09/11/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813989
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,087.15 09/11/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813991
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,533.65 09/11/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813993
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,000.00 09/11/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813995
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635855
Principal investigator 1 Boehringer Ingelheim International GmbH $19.00 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635863
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635865
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635867
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635869
Principal investigator 1 Boehringer Ingelheim International GmbH $146.16 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635871
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635873
Principal investigator 1 Boehringer Ingelheim International GmbH $6.10 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635875
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635965
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635967
Principal investigator 1 Boehringer Ingelheim International GmbH $20.88 08/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635969
Principal investigator 1 Genentech, Inc. $5,745.00 08/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211644101
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,000.00 08/19/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813981
Principal investigator 1 Boehringer Ingelheim International GmbH $5,312.25 08/18/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635951
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,929.00 08/18/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813983
Principal investigator 1 Astellas Pharma Global Development $9,000.00 08/11/2025 Non-covered Recipient Entity
Retina Associates of Utah P.C.
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185492
Principal investigator 1 Genentech, Inc. $3,300.00 08/06/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211644104
Principal investigator 1 Genentech, Inc. $1,100.00 08/06/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211644107
Principal investigator 1 Boehringer Ingelheim International GmbH $4,233.60 08/04/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635953
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635851
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 08/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635853
Principal investigator 1 Boehringer Ingelheim International GmbH $299.70 07/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635857
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 07/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635859
Principal investigator 1 Boehringer Ingelheim International GmbH $104.40 07/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635861
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 07/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635959
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635961
Principal investigator 1 Boehringer Ingelheim International GmbH $39.44 07/28/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 07/24/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 07/24/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218295
Principal investigator 1 Boehringer Ingelheim International GmbH $452.25 07/23/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635945
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,223.10 07/11/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813977
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $405.50 07/11/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813979
Principal investigator 1 Janssen Research & Development, LLC $14.17 07/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425018
Principal investigator 1 Janssen Research & Development, LLC $402.00 07/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425039
Principal investigator 1 Janssen Research & Development, LLC $4,375.00 07/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425056
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425068
Principal investigator 1 Boehringer Ingelheim International GmbH $94.50 07/07/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635947
Principal investigator 1 Genentech, Inc. $1,499.00 07/07/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1211644040
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635849
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 06/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211579
Principal investigator 1 Boehringer Ingelheim International GmbH $4,795.20 06/23/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635923
Principal investigator 1 Janssen Research & Development, LLC $6,619.00 06/09/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425044
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 06/04/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635921
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,750.00 06/02/2025 Non-covered Recipient Entity
Retina Associates of Utah, PLLC
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220813975
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635847
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635957
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 05/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635937
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 05/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635939
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 05/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635941
Principal investigator 1 Boehringer Ingelheim International GmbH $93.96 05/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635943
Principal investigator 1 Boehringer Ingelheim International GmbH $1,831.95 05/05/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635925
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 05/05/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635927
Principal investigator 1 Boehringer Ingelheim International GmbH $5,312.25 05/05/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635929
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635845
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635931
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 04/23/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635933
Principal investigator 1 Boehringer Ingelheim International GmbH $4.88 04/23/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635935
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.30 04/03/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220792953
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635843
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635917
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 03/31/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425051
Principal investigator 1 Janssen Research & Development, LLC $124.03 03/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425061
Principal investigator 1 Boehringer Ingelheim International GmbH $904.50 03/26/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635907
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 03/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635829
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635831
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 03/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635833
Principal investigator 1 Boehringer Ingelheim International GmbH $85.84 03/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635835
Principal investigator 1 Boehringer Ingelheim International GmbH $7.44 03/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635837
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 03/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635839
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 03/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635841
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635827
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635919
Principal investigator 1 Boehringer Ingelheim International GmbH $4,446.80 02/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635905
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 02/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635913
Principal investigator 1 Boehringer Ingelheim International GmbH $59.16 02/25/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635915
Principal investigator 1 Janssen Research & Development, LLC $24,417.00 02/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 02/05/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184152388
Principal investigator 1 Janssen Research & Development, LLC $2,431.00 02/03/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF UTAH PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175425022
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 02/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635813
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 02/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635815
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 02/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635817
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 02/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635819
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 02/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635821
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 02/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635823
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220635825
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635955
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635909
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 01/27/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635911
Principal investigator 1 Boehringer Ingelheim International GmbH $2,180.15 01/23/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635901
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Retina Associates Of Utah Salt Lake
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220635903

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2022 Amount invested $0.00 1
PY2022 Value of interest $5,000.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $5,000.00 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $5,000.00 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $5,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2019–2022

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2022 US Retina LLC $0.00 $5,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 951869685
PY2021 US Retina LLC $0.00 $5,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 856669021
PY2020 US Retina LLC $0.00 $5,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 714311317
PY2019 US Retina LLC $0.00 $5,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842801